Kelun's Trop2 ADC meets primary endpoints in phase III triple-negative breast cancer trial
Kelun-Biotech Biopharmaceutical Co. Ltd.’s trophoblast cell-surface antigen 2 (Trop2)-targeted antibody-drug conjugate (ADC), SKB-264, met the primary endpoint of progression-free survival (PFS) in a phase III trial in patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer (TNBC), according to an interim analysis.
Biotech Biopharmaceutical Co Kelun Biotech Biopharmaceutical Kelun Biotech Biopharmaceutical Co Ltd Antibody Drug Conjugates Skb 264 Metastatic Triple Negative Breast Cancer
Source: bioworld.com